| The Foley Center At Chestnut Ridge | |
| 621 Chestnut Ridge Parkway, Blowing Rock, North Carolina 28605 | |
| (828) 386-3300 | |
| Name | The Foley Center At Chestnut Ridge |
|---|---|
| Location | 621 Chestnut Ridge Parkway, Blowing Rock, North Carolina |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 92 |
| Occupancy Rate | 76.3% |
| Medicare ID (CCN) | 345045 |
| Legal Business Name | Liberty Healthcare Group, Llc |
| Ownership Type | Non Profit - Corporation |
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Blocking a single tiny blood vessel in the brain can harm neural tissue and even alter behavior, a new study from the University of California, San Diego has shown. But these consequences can be mitigated by a drug already in use, suggesting treatment that could slow the progress of dementia associated with cumulative damage to miniscule blood vessels that feed brain cells.
Current recommendations that a central catheter is required for continuous intravenous infusion of 3 percent sodium chloride solution should be re-evaluated, according to a study in the American Journal of Critical Care.
Merz Pharmaceuticals today announced that Xeomin (incobotulinumtoxinA), a new botulinum toxin type A for the treatment of adults with cervical dystonia (CD)or blepharospasm, is now commercially available in the U.S. XEOMIN was approved by the U.S. Food and Drug Administration (FDA) on July 30, 2010.
By offering all children in Africa vaccines that protect against bacterial infections, researchers say the number of deaths among children living with sickle-cell anemia could be reduced, Reuters reports. An estimated 200,000 children in Africa annually are born with sickle-cell anemia, a genetic disease "in which red blood cells deform into a sickle shape and cluster, blocking blood flow and causing pain, vulnerability to infections and organ damage."
One of the more intriguing workhorses of the cell, a protein conglomerate called telomerase, has in its short history been implicated in some critical areas of medicine including cancer, aging and keeping stem cells healthy.
› Verified 5 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 13.14 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 12.8 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 64.29 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 3.02 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 6.93 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.94 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.67 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 94.04 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 12.15 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 79.05 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0.89 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 25.52 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 35.46 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 17.42 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.97 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 81.01 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 84.6 | 82.93 |
News Archive
Blocking a single tiny blood vessel in the brain can harm neural tissue and even alter behavior, a new study from the University of California, San Diego has shown. But these consequences can be mitigated by a drug already in use, suggesting treatment that could slow the progress of dementia associated with cumulative damage to miniscule blood vessels that feed brain cells.
Current recommendations that a central catheter is required for continuous intravenous infusion of 3 percent sodium chloride solution should be re-evaluated, according to a study in the American Journal of Critical Care.
Merz Pharmaceuticals today announced that Xeomin (incobotulinumtoxinA), a new botulinum toxin type A for the treatment of adults with cervical dystonia (CD)or blepharospasm, is now commercially available in the U.S. XEOMIN was approved by the U.S. Food and Drug Administration (FDA) on July 30, 2010.
By offering all children in Africa vaccines that protect against bacterial infections, researchers say the number of deaths among children living with sickle-cell anemia could be reduced, Reuters reports. An estimated 200,000 children in Africa annually are born with sickle-cell anemia, a genetic disease "in which red blood cells deform into a sickle shape and cluster, blocking blood flow and causing pain, vulnerability to infections and organ damage."
One of the more intriguing workhorses of the cell, a protein conglomerate called telomerase, has in its short history been implicated in some critical areas of medicine including cancer, aging and keeping stem cells healthy.
› Verified 5 days ago
The Foley Center At Chestnut Ridge Location: 621 Chestnut Ridge Parkway, Blowing Rock, North Carolina 28605 Phone: (828) 386-3300 |